Combination therapy
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
1. A composition comprising:
a) a dimesylate salt of a compound according to formula (I):
wherein:
R 1 and R 2 are, independently, hydrogen or C 1 -C 4 alkyl, or R 1 and R 2 are taken together with the nitrogen atom to which they are attached to form a ring of 3, 4, 5, 6, 7 or 8 member atoms;
A is —CH 2 NH—, —CH(R 10 )—, —C(CH 3 )R 10 )—, —CH 2 CH 2 —, —CH(R 10 )CH 2 —, —CH 2 CH 2 CH(R 10 )—, —CH 2 CH(R 10 )—, or —C(CH 3 )(R 10 )CH 2 —;
each R 10 is, independently, unsubstituted alkyl, substituted alkyl, unsubstituted alkenyl, substituted alkenyl, unsubstituted alkynyl, substituted alkynyl, unsubstituted amino, substituted amino, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, substituted heteroaryl, unsubstituted cycloalkyl, substituted cycloalkyl, unsubstituted heterocycloalkyl, or substituted heterocycloalkyl, any of which may be optionally substituted; and
X 1 and X 2 are, independently, hydrogen, hydroxy, halogen, alkyl, amino, nitro, cyano, carbonylamino, alkoxy, aryloxy, sulfonyl, sulfonamido, thioalkyl, or carboxyl;
wherein a substituted group refers to any substitutable atom of that group substituted, independently, with an acyl, alkoxy, alkyl, alkenyl, alkynyl, amino, aryl, arylalkyl, carbonylamino, carboxyl, cycloalkyl, cycloalkylalkyl, cyano, halo, haloalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, hydroxy, nitro, oxo, phosphonate, sulfinyl, sulfonyl, sulfonate, sulfonamide, thioamido, thiol, thioalkyl, thioxo, or ureido; and
b) a prostaglandin or a prostaglandin analog;
wherein:
the prostaglandin is any compound having a prostanoic acid skeleton:
and
the prostaglandin analog is a compound of formula (IV):
or an optical isomer, diastereomer or enantiomer thereof,
wherein
the dashed lines, independently, indicate the presence or absence of a bond;
A and B are, independently, —(CR a R b )—, wherein each R a and R b is, independently, hydrogen or —C 1-6 alkyl, and n is 0, 1, 2, 3, or 4;
R 1 is —C(O)OR c , —CONHR d , —C(O)NHOH, —CH 2 OH, —S(O) 2 R e , or —C(O)NHS(O) 2 R f ;
R 2 is hydrogen or —C 1-6 alkyl;
R 3 , R 4 , and R 5 are, independently, hydrogen or an alcohol protecting group;
Y is a bond, —O—, —S—, —S(O)—, —S(O) 2 —, —C(R g ) 2 —, —CR h ═CR i —, —NR j —, or —C═C—;
Z is hydrogen, cycloalkyl, heterocyclyl, aryl, or heteroaryl;
R c is hydrogen, —C 1-6 alkyl, —C 1-6 heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl;
R d , R e , and R f are, independently, —C 1-6 alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl;
R g , R h , and R i are, independently, hydrogen, —C 1-6 alkyl, alkoxy, or hydroxy; and
R j is hydrogen or —C 1-6 alkyl.
2. A compound, wherein the compound is a dimesylate salt of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate.
3. A method of treating an ocular disorder in a subject in need thereof, comprising administering to the subject the compound of claim 2 .
4. The method of claim 3 , wherein the ocular disorder is glaucoma.
5. The method of claim 3 , wherein the ocular disorder is a neurodegenerative eye disease.
6. The method of claim 3 , wherein the ocular disorder is dry eye.
7. The method of claim 3 , wherein the ocular disorder is ocular hypertension.
8. A method of reducing intraocular pressure in a subject in need thereof, comprising administering to the subject the compound of claim 2 .
9. A composition comprising a dimesylate salt of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate.
10. A method of treating an ocular disorder in a subject in need thereof, comprising administering to the subject the composition of claim 9 .
11. The method of claim 10 , wherein the ocular disorder is glaucoma.
12. The method of claim 10 , wherein the ocular disorder is a neurodegenerative eye disease.
13. The method of claim 10 , wherein the ocular disorder is dry eye.
14. The method of claim 10 , wherein the ocular disorder is ocular hypertension.
15. A method of reducing intraocular pressure in a subject in need thereof, comprising administering to the subject the composition of claim 9 .
16. A pharmaceutical composition comprising a dimesylate salt of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate, and a pharmaceutically acceptable excipient.
17. A method of treating an ocular disorder in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 16 .
18. The method of claim 17 , wherein the ocular disorder is glaucoma.
19. The method of claim 17 , wherein the ocular disorder is a neurodegenerative eye disease.
20. The method of claim 17 , wherein the ocular disorder is dry eye.
21. The method of claim 17 wherein the ocular disorder is ocular hypertension.
22. A method of reducing intraocular pressure in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 16 .